Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?

被引：1
|
作者：
Menis, Jessica [1 ]
Remon, Jordi [2 ]
机构：
[1] Univ & Hosp Trust Verona, Med Oncol Dept, Verona, Italy
[2] Paris Saclay Univ, Inst Gustave Roussy, Villejuif, France
来源：
LANCET RESPIRATORY MEDICINE | 2023年 / 11卷 / 10期
关键词：
CELL LUNG-CANCER; OSIMERTINIB;
D O I：
10.1016/S2213-2600(23)00216-3
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：857 / 859
页数：3
相关论文
共 50 条
  • [1] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
  • [2] Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters
    Estevinho, F.
    Felizardo, M.
    Fernandes, G.
    Figueiredo, A.
    Lopes, A.
    PULMONOLOGY, 2019, 25 (05): : 306 - 309
  • [3] A new standard for EGFR-mutant NSCLC?
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) : 593 - 593
  • [4] A new standard for EGFR-mutant NSCLC?
    David Killock
    Nature Reviews Clinical Oncology, 2019, 16 : 593 - 593
  • [5] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [6] Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
    Wang, P.
    Li, Y.
    Lv, D.
    Ding, L.
    Hong, W.
    Han-Zhang, H.
    Lin, J.
    Zhou, J.
    Wang, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S599
  • [7] EGFR Mutation Testing Using Liquid Biopsy Technology for Patients with Advanced EGFR-Mutant NSCLC
    Seitz, Jan
    Moskalev, Evgeny A.
    Fuchs, Florian
    Haller, Florian
    Hartmann, Arndt
    MODERN PATHOLOGY, 2018, 31 : 750 - 750
  • [8] EGFR Mutation Testing Using Liquid Biopsy Technology for Patients with Advanced EGFR-Mutant NSCLC
    Seitz, Jan
    Moskalev, Evgeny A.
    Fuchs, Florian
    Haller, Florian
    Hartmann, Arndt
    LABORATORY INVESTIGATION, 2018, 98 : 750 - 750
  • [9] Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
    How, Soon Hin
    Liam, Chong Kin
    Abidin, Muhammad Adil Zainal
    Hasbullah, Harissa H.
    Tho, Lye Mun
    Ho, Gwo Fuang
    Nor, Ibtisam Muhamad
    Pang, Yong Kek
    Ho, Kean Fatt
    Thiagarajan, Muthukkumaran
    Ariffin, Roziana
    Samsudin, Azlina
    Omar, Azza
    Tan, Sin Nee
    Ong, Choo Khoon
    Soon, Sing Yang
    Poh, Mau Ern
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1995 - 2005
  • [10] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
    Jassem, Jacek
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
12345